- Home
- SBRA vs GH Comparison
SBRA vs GH Comparison
Compare SBRA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- GH
- Stock Information
- Founded
- SBRA 2010
- GH 2011
- Country
- SBRA United States
- GH United States
- Employees
- SBRA N/A
- GH N/A
- Industry
- SBRA Real Estate Investment Trusts
- GH Medical Specialities
- Sector
- SBRA Real Estate
- GH Health Care
- Exchange
- SBRA Nasdaq
- GH Nasdaq
- Market Cap
- SBRA 4.4B
- GH 3.0B
- IPO Year
- SBRA N/A
- GH 2018
- Fundamental
- Price
- SBRA $19.00
- GH $25.08
- Analyst Decision
- SBRA Strong Buy
- GH Strong Buy
- Analyst Count
- SBRA 11
- GH 17
- Target Price
- SBRA $17.10
- GH $39.31
- AVG Volume (30 Days)
- SBRA 2.1M
- GH 2.5M
- Earning Date
- SBRA 11-04-2024
- GH 11-04-2024
- Dividend Yield
- SBRA 6.28%
- GH N/A
- EPS Growth
- SBRA N/A
- GH N/A
- EPS
- SBRA 0.23
- GH N/A
- Revenue
- SBRA $665,991,000.00
- GH $643,810,000.00
- Revenue This Year
- SBRA N/A
- GH $27.01
- Revenue Next Year
- SBRA $5.02
- GH $18.30
- P/E Ratio
- SBRA $84.08
- GH N/A
- Revenue Growth
- SBRA 22.99
- GH 26.20
- 52 Week Low
- SBRA $12.83
- GH $15.81
- 52 Week High
- SBRA $19.32
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- SBRA 81.76
- GH 42.70
- Support Level
- SBRA $17.37
- GH $23.07
- Resistance Level
- SBRA $17.65
- GH $27.13
- Average True Range (ATR)
- SBRA 0.35
- GH 1.30
- MACD
- SBRA 0.17
- GH 0.20
- Stochastic Oscillator
- SBRA 87.88
- GH 49.51
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.